Karthik Chetlapalli
About
Copy Link
Biography
Karthik is currently a Yale medical student, having had diverse experiences across medicine and biotech. He began his career at the University of Southern California in Los Angeles. While an undergrad, he worked as a synaptic electrophysiology research assistant, an ambulance EMT, and a vice president for a student-run veteran’s rehabilitation organization. Later as a business development intern for Neurocrine Biosciences, he screened academic institutes and upcoming startups for novel neuropsychiatric therapeutics.
During his Master’s, Karthik explored the prospect of new stem-cell-based methods for use in antifibrotics and next-generation (CAR) cell therapy. While he worked as a lab assistant for kidney organoid research at USC, Karthik started and led his non-profit SROA to tackle stem cell treatment fraud. More recently, Karthik worked at City of Hope as a clinical genetics assistant, supporting genetic counseling and precision medicine for patients facing cancer. As a current medical student, Karthik is interested in clinical trial equity, cancer outcomes, immuno-oncology therapeutics, and the power of venture capital in advancing medicine.
Karthik earned an M.S. in Stem Cell Biology and a B.S. in Neuroscience with a minor in Health Care Studies from the University of Southern California.
Education & Training
- MS
- University of Southern California, Stem Cell Biology
- BS
- University of Southern California, Neuroscience (2021)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Alfred Lee, MD, PhD
Harlan Krumholz, MD, SM
Kunal Potnis, MD
Satoko Ito, MD, PhD
Publications
2024
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 2024, 145: 127-140. PMID: 39374533, PMCID: PMC11738035, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchCitationsAltmetricConceptsStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcome
Academic Achievements & Community Involvement
Copy Link
News
Copy Link